Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and ...

Bee Jarvis suffers from a rare skin condition that affects just five or six in every 10,000 people, as she dreams of moving to Australia away from the rainy British weather ...

Remibrutinib shows significant complete response rates across 3 chronic inducible urticaria subtypes in the phase 3 RemIND trial.

A woman who is allergic to rain and cold weather has spoken about when she developed the condition and the impact of it on ...

The trial is assessing remibrutinib's safety, tolerability and efficacy in adults with CIndU unresponsive to ...

Novartis reports positive topline results from pivotal phase III RemIND trial of oral remibrutinib in chronic inducible urticaria: Basel Thursday, February 19, 2026, 13:00 Hrs [IS ...

Swiss pharma giant Novartis has announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU).

Next time you’re complaining about miserable weather, look on the bright side – at least it won’t cover your body in hives ...

Novartis announced positive Phase III results from the RemIND trial showing that the oral BTK inhibitor remibrutinib achieved significantly higher complete response rates than placebo in three major ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

Novartis is on course to expand the label for its recently approved oral BTK inhibitor Rhapsido, after chalking up a win in chronic skin disorder chronic inducible urticaria (CINDU).

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was ...